To further validate the regulatory role of USP15 in NF-κB pathway activity, we introduced the NF-κB signaling pathway inhibitor BAY11-7082 to the bladder cancer cell group with heightened USP15 expression. Here, NFKB1 is linked to urinary bladder carcinoma.